Interview with Jessica Shull, European Lead from Digital Therapeutics Alliance, who is presenting at the inaugural Disruptive Technologies in Pharma conference
The highly anticipated launch of the inaugural Disruptive Technologies in Pharma conference is set to take place in London on 20th-21st January 2020. The conference will provide industry leaders with the unique opportunity to hear first-hand how the pharmaceutical industry is being shaped by developments in AI, Machine Learning, Internet of Things and Blockchain, while newer categories such as Prescription Digital Therapeutics begin to offer truly disruptive benefits.
For those interested in attending, an early bird saving of £200 for bookings made by 31st October is available.
Ahead of the two-day event, SMi caught up with speaker Jessica Shull, European Lead, Digital Therapeutics Alliance, presenting on “What is required for a DTx product to be successful?” Jessica is European Lead for the Digital Therapeutics Alliance. She is also Digital Health Manager on clinical trials and Big Data projects for respiratory disease at Bellvitge Hospital in Barcelona. She worked 13+ years with the WHO on digital health projects for health system strengthening. Consultancies include World Bank, mHealth app evaluation guidelines for Europe, and EU regulatory process for digital diagnostics. She has a MSc from the Medical College of Georgia, an MA form the University of Trento (Italy) and is pursuing a PhD in BioMedicine at the University of Barcelona.
Preview of Jessica’s Interview:
What is your background in disruptive technologies and how do you contribute to driving healthcare disruption with your everyday work?
“I got started in digital health right out of graduate school, designing the 3D content for virtual surgery devices. We used the Visible Human data from the National Institutes of Health in Washington DC – really cutting edge at the time. The idea was to teach nurses and surgeons virtually, to save students and residents from unnecessary error on human subjects. Since that time I’ve always gravitated toward disruptive solutions in medicine…”
What do you consider as drivers of digital transformation and why do you think there is a need for such changes in the global healthcare landscape?
“No system is designed perfectly right out of the box. This is why we have iterations in software development and amendments to a country’s constitution. I would say the driver for digital transformation is necessity. Healthcare across the globe has chasms where patients fall through, and if digital can serve those people and even current patients better, we have a duty to shape that offering…”
For the full interview and event details with the complete speaker line-up, the brochure is available to download on the website.
Disruptive Technologies in Pharma
20th – 21st January 2020
London, UK
WASHINGTON – Today, the U.S. Department of the Treasury (Treasury), as Chair of the Committee…
WASHINGTON—Today, the U.S. Department of the Treasury’s Community Development Financial Institutions Fund (CDFI Fund) and…
Washington – The findings from the annual survey of U.S. portfolio holdings of foreign securities…
WASHINGTON – The U.S. Department of the Treasury hosted a roundtable on October 30 with…
WASHINGTON – The United States and the People’s Republic of China held the sixth meeting…
WASHINGTON — Today, the Department of the Treasury’s Office of Foreign Assets Control (OFAC) sanctioned…